Pfizer has revised its revenue forecast upward, signaling continued strong financial performance for the pharmaceutical company. The adjustment comes amid a broader industry boom driven by high demand for medications and vaccines. Analysts suggest the company’s latest outlook reflects sustained profitability, particularly in its core therapeutic and vaccine segments. The move underscores how pharmaceutical firms are capitalizing on market conditions to extend their financial gains.
Pfizer raises revenue forecast, extending pharma windfall Crain's New York
